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ABSTRACT
Background: In the United States, human immunodeficiency virus (HIV) remains a substantial public health issue. There is
evidence that the use of antiretroviral medications such as pre-exposure prophylaxis (PrEP) can be a safe and effective primary
prevention strategy to reduce new cases of HIV infection. Provider practice behavior as it relates to prescribing PrEP and the
potential impact on specific vulnerable populations needs increased attention. Few studies have evaluated the attitudes of
physicians towards ethical issues related to prescribing PrEP.
Methods: The purpose of the present literature review was to evaluate provider attitudes toward the ethics of prescribing PrEP for
individuals at risk of acquiring HIV infection. Searches of the PubMed and Cochrane databases were conducted. Three reviewers
independently assessed the relevance of articles and discarded those not directly related to the attitudes of physicians toward
ethics of the cost, safety, and resource allocation of PrEP. A total of twenty-one articles were included in the review.
Results: Provider attitudes and perceptions focused on three areas: resource allocation, cost, and safety or effectiveness of PrEP.
Providers who were hesitant in prescribing PrEP were concerned with the availability of resources, patient adherence, risk of drug
resistance, and toxicity. In the studies reviewed, few providers had prescribed PrEP; however, prescribing practices trended
upward with time and awareness.
Conclusions: Realization of the benefits of PrEP will require a utilitarian ethical approach to identifying the populations that will
benefit most, monitoring for adverse effects, addressing costs, and educating and training providers to prescribe PrEP responsibly.
Ensuring that PrEP fulfills its potential as part of a combination regimen for HIV prevention requires identification of additional
evidence, education, support services, and resources that are needed, as well as the regulatory framework and cost scenarios for
access to PrEP.
Key words: HIV, pre-exposure prophylaxis, ethics, utilitarianism, PrEP, physician
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a method for individuals who are at high risk of acquiring
HIV infection to take a daily antiretroviral medication to
decrease their risk of infection. The medication consists of
two medicines, tenofovir and emtricitabine, in one pill. In
July 2012, this medication (brand name Truvada) was
approved by the Food and Drug Administration (FDA) for
use as PrEP in HIV-uninfected individuals who are at a high
risk of acquiring HIV infection (U.S. Food & Drug
Administration, 2012). PrEP is taken daily in order to build
up and maintain an effective concentration of the
medication in the blood system to be protective against the
HIV virus. The medication reduces the risk of the virus
binding to CD4 cells and replicating (U.S. Food & Drug
Administration, 2012). Although PrEP helps to prevent a
high-risk individual from acquiring HIV, condoms should
continue to be used as an additional barrier to other sexually
transmitted infections (CDC, 2016b). According to the
CDC, daily use of PrEP can reduce the risk of acquiring
HIV from sexual intercourse by up to 90%, and, for

INTRODUCTION
In the United States and around the world, the human
immunodeficiency virus (HIV) remains a substantial public
health issue. In the United States, there are an estimated 1.2
million people living with HIV (Centers for Disease Control
[CDC], 2016a). In 2015, there were 39,513 new diagnoses
of HIV (CDC, 2016a). Over recent years, there have been
decreases in HIV incidence; however, these decreases are
not consistent among all groups. The populations most
affected by HIV are gay and bisexual men, who account for
82% of new diagnoses among males (CDC, 2016a).
Heterosexuals and injecting drug users also continue to be
included in new HIV diagnoses, and African Americans
continue to experience the greatest burden of HIV compared
to other races (CDC, 2016a).
There is evidence that the use of antiretroviral medications
can be a safe and effective way to prevent HIV infection
(Sugarman et al., 2014). Pre-exposure prophylaxis (PrEP) is
http://www.gapha.org/jgpha/
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individuals who inject drugs, it can reduce the risk by up to
70% (CDC, 2016b).

Although general knowledge about and support for PrEP
have increased since the FDA approved Truvada and the
CDC released the prescribing guidelines, knowledge of
PrEP among providers has increased only slightly, and
prescribing rates remain relatively low (Castel et al., 2015).
The willingness of physicians to prescribe PrEP has
significant implications for PrEP access; however, few
studies have evaluated the attitudes of physicians towards
the ethics of the cost, safety, and resource allocation of
prescribing PrEP.

PrEP and Ethical Decision-Making
Contemporary public health strategies to prevent disease
and promote wellness can be analyzed through the lens of
established ethical models for decision making. One of these
models, utilitarianism, was developed in the 19th century by
Jeremy Bentham and John Stuart Mill to determine which
laws were morally best for legislators to provide the greatest
balance of good over evil (Velasquez et al., 2015).
Utilitarianism has become a widely used ethical approach to
decision making. These decisions are most commonly those
that affect a large group of people, where the action in
question provides the most good and does the least amount
of harm. The HIV epidemic and the advent of PrEP provide
an instructive example of the complexities of human health
behaviors and utilitarian ethical decision-making in public
health.

METHODS
The purpose of this literature review was to evaluate
provider attitudes toward the ethics of use of PrEP for
individuals at high risk for acquiring HIV infections.
Provider concerns regarding the safety, efficacy, and costeffectiveness of the PrEP intervention were evaluated
through the ethical framework of the utilitarian approach to
ethical decision-making. All study protocols were reviewed
and approved by the Georgia Southern University
Institutional Review Board.

Understanding physicians’ attitudes toward the ethical
considerations of prescribing PrEP is an essential
component in increasing our awareness and understanding
of
practice
patterns
impacting
population-level
administration of PrEP. Primary care providers (PCPs)
accomplish the first step in prescribing PrEP to the
populations most at risk for acquiring HIV, for physicians
must first identify appropriate courses of action. Then, often
using utilitarian ethics, they consider the pros and the cons
that are the results of the actions and choose the action that
will provide the greatest benefit (Velasquez et al., 2015).
The attitudes of physicians towards the cost, safety, and
resource allocation aspects of PrEP can either hinder or
promote its use. The medications cost an estimated $12,000
per person per year; however, mathematical modeling
suggests that, over time, PrEP programs have the potential
to save costs for the healthcare system, showing a positive
return on investment (Cappelletti, 2016). Under certain
conditions, it is ethical to provide PrEP even when the
supply of antiretrovirals available for treatment is low,
because maximizing of the overall health benefits means
giving priority to those who will respond best to treatment
and survive the longest (Rennie, 2013; Macklin et al.,
2012). In regards to safety, although some studies have
shown that PrEP is effective at reducing the incidence of
new HIV infections, it could take years to compile sufficient
evidence of the clinical safety and efficacy of PrEP for
various populations. These cost and safety considerations
can influence decisions on resource allocation. According to
Hankins, Macklin, & Warren (2015), cost-effectiveness
studies guide resource allocation decisions by indicating
where resources can be applied for greatest impact. Hankins
et al. (2015) argue that the outcomes-oriented utilitarian
principle should guide resource allocation in conjunction
with a prioritarian approach, which gives special
consideration to socially and economically disadvantaged
groups. The combination of prevailing ethical approaches
and practical implications such as cost, safety, and resource
allocation, can profoundly influence the decisions
physicians make regarding PrEP recommendation and
prescription.
https://digitalcommons.georgiasouthern.edu/jgpha/vol7/iss1/4
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This literature review included peer-reviewed journal
articles published between 2014 and 2017 reporting on
physician attitudes towards prescribing PrEP. Only papers
written in English were included. Data were collected by
use of the PubMed and Cochrane search engines available
through the Georgia Southern University Library GALILEO
database system. To ensure that all articles that were eligible
for review were captured, a broad initial search strategy was
used for literature identification with the terms: “preexposure prophylaxis” OR “PrEP,’ plus “HIV,” plus
“physician hesitation,” and “Ethics” OR “Bioethics” OR
“ethical issues” OR “normative” OR “ethical guidelines.”
A second search was conducted to screen articles for
keywords contained in titles and abstracts using the search
terms: “PrEP allocation” OR “high risk” OR “PrEP plus
efficacy” OR “PrEP plus HIV plus high risk” OR “PrEP
plus resource plus allocation” OR “resource” AND “ethics”
OR “ethical” OR “utilitarian” OR “utilitarianism” OR
“physician” OR “provider” OR “safety” OR “effectiveness”
OR “cost PLUS benefit” OR “debate” OR “dilemma.” Then
a search was conducted through PubMed for the terms “preexposure prophylaxis” AND “HIV” AND “physician” OR
“provider” AND “ethics” AND “attitudes.” Finally, a search
was conducted in PubMed using the terms “pre-exposure
prophylaxis” OR “PrEP” AND “HIV” AND “physician”
OR “provider” AND “ethics” OR “ethical” OR “bioethics.”
Duplicate articles were eliminated.
Three reviewers independently assessed the relevance of
articles and discarded those not directly related to
physician’s attitudes towards the ethics of the cost, safety,
and resource allocation of PrEP. The first reviewer
conducted the initial analysis. The second and third analyses
were conducted, separately, by two additional reviewers.
The criteria for inclusion were that each article must
explicitly address considerations of PrEP treatment
allocation, cost, safety, and/or efficacy, and must report on
20
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healthcare provider perspectives. Articles that did not
initially meet criteria were discussed by the reviewers, and
only those articles that had full agreement were included.
Twenty-one articles were ultimately included in this
literature review.

A systematic review of 13 studies found that key
considerations in assessing cost-effectiveness of PrEP are
cost, the epidemic context, individual adherence, PrEP
program coverage, and prioritization strategy (Hankins,
Macklin, and Warren, 2015). The researchers felt that PrEP
could be a cost-effective addition to HIV prevention
programs, particularly when those at highest risk of HIV
exposure are prioritized (Hankins, Macklin, and Warren,
2015). They also felt that paying for PrEP, when access to
antiretroviral therapy is not universal, is an issue that
requires reflection. To fulfill the public health need for
PrEP, the researchers felt that PrEP introduction activities
will enable policy-makers and program planners to answer
the questions of who can benefit most from PrEP, how to
provide it safely and efficiently, how to integrate PrEP into
combination treatment and prevention programs, and what
kind of health system support is needed to ensure
implementation (Hankins, Macklin, & Warren, 2015).

RESULTS
The literature review focused on provider attitudes
regarding prescribing PrEP, including resource allocation,
cost, and safety or effectiveness of the drug. Several of the
researchers cited in the literature had formulated their own
literature reviews or had conducted their own research on
prescriber attitudes towards PrEP.
Resource Allocation
Some authors argued that resources allocated to the
distribution of PrEP can negatively affect the availability of
resources for HIV treatment. Sugarman & Mayer (2014)
concluded that questions regarding resource allocation will
not be easy to address if related factors, including cost,
safety, and efficacy, remain in question. A notable
consideration is that there are other effective HIV
prevention methods, such as educational forums,
counseling, and condom use. Sugarman & Mayer (2014)
raised the point that funding for HIV prevention and
treatment can be considered a draw on a larger, limited pool
of general funding for health concerns ˗˗ a consideration that
demands a more complex and broad assessment of PrEP
funding allocation. A second aspect of resource allocation is
the problem of determining which demographic ˗˗ not
medical ˗˗ groups should be prioritized for PrEP, as
insufficient resources exist to distribute the treatment
regimen equally to all who may benefit from it.

PCPs and infectious disease physicians in the US Air Force
(USAF) participated in a cross-sectional survey examining
knowledge, attitudes, and beliefs toward HIV and PrEP
(Hakre et al., 2016). Barriers to PrEP utilization included
concerns about costs, viral resistance, patient adherence, and
side effects of medication. The low uptake of PrEP by
USAF providers may be related to concerns reported in the
survey and uncertainty about costs.
A study by Castel et al. (2015) examined PrEP knowledge,
experience, and likelihood of prescribing PrEP among HIV
providers in Miami, FL, and Washington, DC. As stated in
this report, 53% of the providers were concerned about the
cost of the drug and reimbursement procedures (Castel et
al., 2015). Latent class analysis was conducted to divide the
providers into two groups: class one, who were identified as
perceiving PrEP as less effective with substantial barriers;
and class two, who perceived PrEP as being moderately
effective with few barriers. Class two had a slightly higher
probability of agreeing that cost might pose a substantial
barrier (Castel et al., 2015). Both groups of providers also
identified the risk for drug resistance and risk compensation
as potential barriers to PrEP use—findings that were
consistent with the results of other studies of potential
physician providers of PrEP (Blumenthal et al., 2015;
Caceres et al., 2015; Castel et al., 2016; Hakre et al., 2016;
Hankins et al., 2015; Karris et al., 2014; Krakower et al.,
2014; Krakower et al., 2015; Krakower and Mayer, 2016;
Puro et al., 2013; Smith et al., 2016).

Cost
Several studies focused on cost-effectiveness, investigating
whether the benefits of preventing HIV through
administering PrEP outweigh the costs of PrEP (Hankins et
al., 2015; Hakre et al., 2016; Karris et al., 2014). Funding
PrEP while other potentially more cost-effective HIV
prevention interventions remain underfunded may have high
opportunity costs, diverting resources from early initiation
of anti-retroviral therapy or other prevention strategies
(Hankins, Macklin, and Warren, 2015).
Puro et al. (2013), through a focus group and literature
review, developed a questionnaire that was administered to
a convenience sample of Italian HIV specialists during
educational courses in two regions and an online survey in
February-May 2012. The participants were asked if they
would allocate the costs of PrEP to the National Health
System (NHS). Most respondents believed that NHS should
sustain PrEP costs entirely, in all (28%) or selected (9%)
cases (i.e., conception), or partially, based on patient’s
income (29%) (Puro et al., 2013). Regarding financial
sustainability, although it was deemed too expensive, most
specialists advocated NHS support of PrEP costs to ensure
equity of access, consistent with other studies in which
healthcare providers recognized cost as a major barrier for
patients and would like for public programs to pay for PrEP
if patients cannot afford it (Puro et al., 2013).
http://www.gapha.org/jgpha/
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Safety/Effectiveness
Prescribers were hesitant in prescribing PrEP because the
effectiveness of the drug was considered equivocal
(Blumenthal et al., 2015; Caceres et al., 2015; Castel et al.,
2016; Hakre et al., 2016; Hankins et al., 2015; Karris et al.,
2014; Krakower et al., 2014; Krakower et al., 2015;
Krakower and Mayer, 2016; Puro et al., 2013; Smith et al.,
2016). PCPs reported lack of knowledge or training about
PrEP as the main barrier in prescribing PrEP and in
providing PrEP education to patients (Hakre et al., 2016).
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A study by Blumenthal et al. (2015) explored prescriber
attitudes about efficacy through a 35-question, selfadministered survey that was given to clinicians (N=233)
who attended HIV-related conferences and meetings in New
York, San Diego, and Los Angeles. The survey focused on
knowledge and experience with PrEP and evaluated
perceived advantages and disadvantages of PrEP being
provided by clinicians who did and did not generally care
for HIV-infected persons and high-risk, HIV-uninfected
individuals (Blumenthal et al., 2015). The results showed
that 40% of these providers were hesitant to prescribe PrEP
because of patient resistance to the drug. Most (>80%)
providers agreed that new studies showing efficacy, patient
request, ease of patient obtaining PrEP, and
recommendations from CDC would likely increase their use
of PrEP (Blumenthal et al., 2015). Many of the reports
indicated that patients would become resistant to the drug
and that it would essentially be ineffective, which limited
their willingness to prescribe PrEP (Blumenthal et al., 2015;
Caceres et al., 2015; Castel et al., 2016; Hakre et al., 2016;
Hankins et al., 2015; Karris et al., 2014; Krakower et al.,
2014; Krakower et al., 2015; Krakower and Mayer, 2016;
Puro et al., 2013; Smith et al., 2016).

their patient population. In a survey given to clinicians, 74%
of respondents reported support for provision of PrEP, but
only 9% had prescribed it. Of those surveyed, 34% reported
that PrEP was not germane to their practice (Karris et al.,
2013).

A study by Karris et al. (2013) examined prescriber attitudes
towards the safety of PrEP through a 10-question survey
that was given to infectious disease specialists (N = 573)
who belonged to The Emerging Infections Network of the
Infectious Diseases Society of America. The survey
inquired about the participants’ HIV practice, to whom they
had provided or would provide PrEP, how they assessed
eligibility, how they measured adherence, when PrEP would
be discontinued, and what perceived barriers existed (Karris
et al., 2014). When asked why physicians would not provide
PrEP, 77% were worried about adherence and the risk for
future resistance, 53% did not want to use potentially toxic
drugs for healthy persons, and 53% felt there was
insufficient evidence for the efficacy of PrEP (Karris et al.,
2014).

Several studies suggested that PrEP awareness and
willingness to prescribe it are generally increasing (Castel et
al., 2015; Hakre et al., 2016; Karris et al., 2015; Krakower
et al., 2015; Krakower and Mayer, 2012; Krakower and
Mayer, 2016; Puro et al., 2013; Smith et al., 2016). In one
study conducted before and after the release of PrEP trial
results, primary care clinicians reported that awareness of
PrEP had increased from 24% in 2009 to 66% in 2015
(Smith et al., 2015). In 2009, 1% of participants reported
having prescribed PrEP; in 2015, 7% reported having
prescribed PrEP. Willingness to prescribe PrEP was
associated with experience in treating patients with
antiretroviral medications for HIV.

Prescriber Practices
Even though prescribers were aware of PrEP and its use,
many were reluctant to prescribe it (Castel et al., 2015;
Hakre et al., 2016 Krakower et al., 2015; Karris et al., 2015;
Krakower and Mayer, 2012; Krakower and Mayer, 2016,
Puro et al., 2013; Smith et al., 2016). For example, a survey
of 184 clinicians working for a New England AIDS
Educational and Resource Center was conducted to
investigate prescribing practices (Krakower et al., 2015).
The results indicated that clinicians were not readily
prescribing PrEP. Of the respondents, 75% reported being
aware of CDC PrEP guidelines, but only 19% had
prescribed it. Having a higher percentage of patients
infected with HIV was associated with a history of
prescribing PrEP. This study was conducted at an institution
specializing in HIV care, rather than in a primary care
setting, a fact pointed out by survey respondents who
believed that primary care and sexual health clinics may be
more appropriate settings for prescription of PrEP.

The studies included in this review discussed the importance
of resource allocation, safety, effectiveness, and cost
benefits for prescribing PrEP. Realization of the societal
value of PrEP will require identifying individuals who are
most likely to benefit from it, monitoring for adverse
effects, addressing costs, and training providers to prescribe
PrEP responsibly (Krakower and Mayer, 2012). Many
prescribers are hesitant in prescribing PrEP, mainly due to
lack of knowledge and efficacy of the drug. Ensuring that
PrEP fulfills its potential as part of a HIV prevention
regimen requires establishing additional evidence,
education, support services, and resources, as well as the
regulatory framework and cost scenarios for access to PrEP
(Hankins, Macklin, and Warren, 2015).

Several studies indicated that some prescribers supported
PrEP but had not prescribed it because it was not relevant to
https://digitalcommons.georgiasouthern.edu/jgpha/vol7/iss1/4
http://www.gapha.org/jgpha/
DOI: 10.21633/jgpha.7.104

Puro, et al., (2013) assessed prescribers’ knowledge about
PrEP and their willingness to prescribe it. HIV specialists
(N=311) responded to a survey regarding attitudes toward
PrEP. Of these, 69% rated their own familiarity with PrEP
as being minimum or sufficient, and 70% reported that they
would prescribe PrEP. These results support broader
findings indicating a higher willingness to prescribe PrEP
among HIV specialists (Puro et al., 2013).
A survey was given to providers treating individuals with
HIV to evaluate their willingness to prescribe PrEP (Castel
et al., 2015). Of the participants, 50% reported that they
were infectious disease specialists, and 75% reported that
they were PCPs. However, only 17% of the HIV providers
reported that they had prescribed PrEP, with slightly over
half of the respondents reporting belief in the efficacy of
PrEP.

DISCUSSION/CONCLUSIONS

The cost of PrEP has been cited as a provider concern, but
the extent to which cost acts as a barrier remains unclear.
Perception of cost as a barrier was associated with
specialization in infectious diseases and/or HIV care. In a
study of 573 infectious disease specialists, cost was cited as
the main barrier and, in another study of 311 HIV
specialists, was cited as the second largest barrier. Two
22
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other studies (N = 403, N = 233), surveying a wider mix of
providers, found that cost concerns were not among the
highest perceived barriers (Blumenthal et al., 2015; Hakre et
al., 2016; Karris et al., 2014; Puro et al., 2013).
Due to the considerable expense of the drug, the issue of
cost as a prohibitive factor in utilization of PrEP for patients
is substantial. However, a utilitarian analysis of cost factors
would aim to place these concerns in the broader context of
healthcare accessibility, particularly for the high-risk
populations that the drug regimen would benefit. The costeffectiveness of PrEP, from a utilitarian standpoint, would
be determined by evaluating its effect on populations rather
than individuals (Mandal, Ponnambath, & Parija, 2016). A
limitation of the current body of research is that provider
survey items regarding cost are likely to be interpreted at the
individual level, imputing the cost to each patient. Further
research investigating the barrier of price on high-risk
populations most likely to derive the greatest benefits from
the drug is warranted to clarify the relationship between
individual and population-level ethical issues.

Considering disease burden, costing information, and
efficacy, cost-effectiveness studies that illustrate the
utilitarian principle at work can provide an initial indication
of the potential effects of PrEP programs. In regard to
administration of PrEP and ethics, cost-effectiveness
becomes an issue. Unlike the context of private
prescriptions, if PrEP becomes a state-recommended
intervention, the question of cost versus benefit arises. Some
of the questions posed by PrEP are not specific to HIV
prophylaxis, but are standard public health considerations
about resource allocation and striking a balance between
individual benefits and public good. To increase access to
PrEP, we need to understand the cost of PrEP and establish
who is going to pay for it. Clinicians who prescribe PrEP
have an ethical obligation to be aware of the current and
emerging data concerning PrEP and the ethical issues
associated with its use.

Among providers, the effectiveness of PrEP and its potential
for toxic side effects were oft-cited concerns. In a study of
39 HIV care providers, participants discussed the issue of
patient adherence to medication regimens as a barrier to
PrEP efficacy (Krakower et al., 2014). Whether provider
concerns over PrEP efficacy in all the studies reviewed were
related to adherence, rather than efficacy of the drug
regimen, is unclear; however, patient adherence was
frequently cited as a reservation.

Regarding ethics and PrEP, prescribers may have a moral
issue in which they believe that prescribing PrEP will
encourage risky behavior (Puro et al., 2013; Krakower et al.,
2015). There is also a concern that PrEP may lead to drug
resistance, with resulting decreased efficacy of populationlevel treatment; if this is the case, it may be argued that it is
not ethical to prescribe it (Venter, Allais, and Richter,
2014). The urgent-need principle states that medical needs
of people give rise to moral claims to the health care
resources necessary to meet those needs, that equally urgent
needs give rise to equal moral claims, and that more urgent
needs give rise to stronger moral claims (Brock et al., 2003).
The urgent-need principle can be combined with the
utilitarian principle in setting priorities for allocating PrEP,
with the principle of equity giving priority to stigmatized
and marginalized populations, such as men who have sex
with men, sex workers, people who inject drugs, and young
women and serodiscordant couples (Hankins, Macklin, and
Warren, 2015). Introduction of PrEP will enable policymakers and program planners to answer the questions of
who can benefit most from PrEP, how to provide it safely
and efficiently, how to integrate PrEP into combination
treatment and prevention programs, and what kind of health
system support is needed to ensure implementation
(Hankins, Macklin, and Warren, 2015).

A generally positive attitude toward the provision of PrEP
was associated with provider knowledge and experience
with PrEP, suggesting that provider education will be
involved in shaping how PrEP is positioned as a preventive
intervention for high-risk populations. Blumenthal et al.
(2015) found that 80% of 233 providers reported that they
would be more open to prescribing PrEP if more data on
safety and efficacy become available. As levels of provider
education increase, a demand for comparative data between
established HIV prevention methods and PrEP intervention
is likely to arise among professionals seeking a more
complete understanding of whether the benefits of PrEP and
other methods justify the costs.
At present, PrEP provision is generally low (Karris et al.,
2014; Castel et al., 2015; Krakower & Mayer, 2016; Hakre
et al., 2016). In keeping with reports that providers would be
more open to prescribing PrEP after gaining greater
certainty of its safety and efficacy, Smith et al. (2016)
reported a slow increase in PrEP provision over a three-year
span as PrEP awareness grew among the medical
community. Still, as of 2015, only 7% of participants
reported having prescribed PrEP, suggesting that some
providers may be finding compelling reasons not to provide
it. Inquiries should focus on how the oft-cited factors of
adherence, toxicity, and the substantial cost of the drug
regimen might be affecting provider perspectives on the
potential for PrEP to reduce HIV transmission.

http://www.gapha.org/jgpha/
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Overall, few participants reviewed cited the issue of
resource allocation among their chief concerns about PrEP.
In the context of the provider-patient relationship, the distal,
population-level impact of PrEP resource provision on
availability of other HIV treatments may be a less salient
consideration in provider decision-making. Further, resource
allocation for healthcare varies considerably by country,
suggesting that the question of how providers view the
practice of drawing from limited funding for PrEP may vary
according to culture-specific perceptions of resource
availability and distribution (Davis, Stremikis, Schoen, &
Squires, 2014).

Conducting a comprehensive literature review, rather than a
systematic review, allowed review and evaluation of a wide
range of literature. This approach provided the flexibility to
engage the broad knowledge base in the published literature;
however, it has limitations. A comprehensive literature
23

Georgia Public Health Association

23

Journal of the Georgia Public Health Association, Vol. 7, No. 1 [2017], Art. 4

J Ga Public Health Assoc (2017), Vol. 7, No. 1

The innovative use of Truvada for the prevention of HIV
infection represents a new development in the fight against
the spread of HIV. If PrEP can be shown to have a positive
net benefit to high-risk populations and these communities,
public health professionals can lead the call for policies and
programs that make the drug regimen more accessible to
vulnerable populations. Current data suggest that decisionmaking at the provider level is stalled by the lack of data
pertaining to PrEP safety and efficacy. Further, providers
are hesitant to support the prevention method because it
simply is not affordable for many patients. Further research
into the safety and efficacy of PrEP is needed in order to
build a case for the public benefit of devoting resources to
the allocation of PrEP that would withstand a utilitarian
analysis. If data demonstrate that spending on PrEP is likely
to reduce HIV transmission rates in high-risk communities,
advocates can push for policies that would help lower the
cost of PrEP for patients, and efforts to educate providers on
the benefits of PrEP will meet with greater success.
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